285 related articles for article (PubMed ID: 32215583)
1. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
Dess RT; Sun Y; Jackson WC; Jairath NK; Kishan AU; Wallington DG; Mahal BA; Stish BJ; Zumsteg ZS; Den RB; Hall WA; Gharzai LA; Jaworski EM; Reichert ZR; Morgan TM; Mehra R; Schaeffer EM; Sartor O; Nguyen PL; Lee WR; Rosenthal SA; Michalski JM; Schipper MJ; Dignam JJ; Pisansky TM; Zietman AL; Sandler HM; Efstathiou JA; Feng FY; Shipley WU; Spratt DE
JAMA Oncol; 2020 May; 6(5):735-743. PubMed ID: 32215583
[TBL] [Abstract][Full Text] [Related]
2. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Tran PT; Lowe K; Tsai HL; Song DY; Hung AY; Hearn JWD; Miller S; Proudfoot JA; Deek MP; Phillips R; Lotan T; Paller CJ; Marshall CH; Markowski M; Dipasquale S; Denmeade S; Carducci M; Eisenberger M; DeWeese TL; Orton M; Deville C; Davicioni E; Liauw SL; Heath EI; Greco S; Desai NB; Spratt DE; Feng F; Wang H; Beer TM; Antonarakis ES
J Clin Oncol; 2023 Feb; 41(6):1307-1317. PubMed ID: 36367998
[TBL] [Abstract][Full Text] [Related]
3. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
4. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
[TBL] [Abstract][Full Text] [Related]
5. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
6. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
Stish BJ; Pisansky TM; Harmsen WS; Davis BJ; Tzou KS; Choo R; Buskirk SJ
J Clin Oncol; 2016 Nov; 34(32):3864-3871. PubMed ID: 27480153
[TBL] [Abstract][Full Text] [Related]
7. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
[TBL] [Abstract][Full Text] [Related]
8. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
[TBL] [Abstract][Full Text] [Related]
9. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
Kishan AU; Tendulkar RD; Tran PT; Parker CC; Nguyen PL; Stephenson AJ; Carrie C
Eur Urol Oncol; 2018 May; 1(1):3-18. PubMed ID: 31100226
[TBL] [Abstract][Full Text] [Related]
12. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
[TBL] [Abstract][Full Text] [Related]
13. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data.
Sood A; Keeley J; Palma-Zamora I; Chien M; Corsi N; Jeong W; Rogers CG; Trinh QD; Peabody JO; Menon M; Abdollah F
Ann Surg Oncol; 2022 Oct; 29(11):7206-7215. PubMed ID: 35608801
[TBL] [Abstract][Full Text] [Related]
14. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
Ost P; Lumen N; Goessaert AS; Fonteyne V; De Troyer B; Jacobs F; De Meerleer G
Eur Urol; 2011 Oct; 60(4):842-9. PubMed ID: 21514039
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
Kabarriti R; Ohri N; Hannan R; Tishbi N; Baliga S; McGovern KP; Mourad WF; Ghavamian R; Kalnicki S; Guha C; Garg MK
Pract Radiat Oncol; 2014; 4(6):409-14. PubMed ID: 25407863
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy.
Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
[No Abstract] [Full Text] [Related]
18. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
[TBL] [Abstract][Full Text] [Related]
19. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
Tay KJ; Polascik TJ; Howard LE; Salama JK; Schulman AA; Chen Z; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Clin Genitourin Cancer; 2019 Oct; 17(5):e930-e938. PubMed ID: 31257075
[TBL] [Abstract][Full Text] [Related]
20. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
[Next] [New Search]